[en] [en] PURPOSE: The health impact of dairy products is debated due to their high saturated fatty acid (SFA) content. Emerging evidence suggests that dairy products intake may reduce cardiovascular disease risk, despite their SFA-rich lipids, leading to the "dairy food matrix" concept. Nevertheless, the impact of lipid and SFA intake from whole dairy sources on cardio-metabolic health remains poorly understood. This study investigated the cross-sectional association of SFA intake from various types of dairy products and dairy fat sources with cardio-metabolic outcomes.
METHODS: Data from 1619 participants of the STANISLAS cohort, who underwent extensive metabolic and cardiovascular phenotyping and completed a 133-item food frequency questionnaire covering dairy products and other dairy fat sources, were used. Associations of total dietary lipid, total dietary SFA, and SFA intakes from dairy products and dairy fat sources with metabolic outcomes (metabolic syndrome, hyperlipidemia, type 2 diabetes, prediabetes) and subclinical cardiovascular damages (i.e., arterial stiffness, atherosclerosis, left ventricular mass, diastolic dysfunction) were assessed using mixed models.
RESULTS: Median [interquartile range] lipid consumption via dairy products and dairy fat sources was 23 [15, 34] g/day. Higher total dietary lipid intake was associated with lower arterial stiffness (exp(β) [95%CI]: 0.96 [0.92-0.99]). Total dietary SFA and SFA from dairy products were both inversely associated with left ventricular mass (exp(β) [95%CI]: 0.85 [0.74-0.98], and 0.99 [0.99-0.99], respectively). SFA from dairy fat sources, particularly from Butter, were inversely associated with hyperlipidemia (OR [95%CI]: 0.96 [0.93-0.99] for hypertriglyceridemia, 0.96 (0.93-0.99) for elevated LDLc, 0.95 (0.92-0.98) for elevated non-HDLc, 0.93 (0.89-0.96) for elevated Apolipoprotein B). SFA from Yogurt was inversely associated with Apolipoprotein B (OR [95%CI]: 0.92 [0.86-0.98]).
CONCLUSION: Examining the specific diary matrix subtypes, our results suggest altogether neutral to beneficial associations of SFA from dairy products and dairy fat sources with cardio-metabolic health.
Disciplines :
Public health, health care sciences & services
Author, co-author :
Wagner, Sandra ; Université de Lorraine, Centre d'Investigation Clinique Plurithématique Inserm CIC P 1433, Inserm U1116, CHRU Nancy Brabois, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), 4 rue du Morvan, Nancy, 54500, France
Girerd, Nicolas; Université de Lorraine, Centre d'Investigation Clinique Plurithématique Inserm CIC P 1433, Inserm U1116, CHRU Nancy Brabois, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), 4 rue du Morvan, Nancy, 54500, France. n.girerd@chru-nancy.fr
Lemonnier, Claire; INRAE, CarMeN Laboratory, INSERM, U1060, Univ Lyon, Université Claude Bernard Lyon 1, Bâtiment CENS-ELI 2D, Hopital Lyon Sud, 165 Chemin du Grand Revoyet, Pierre-Bénite, 69310, France
Yena, Kofivi ; Université de Lorraine, Centre d'Investigation Clinique Plurithématique Inserm CIC P 1433, Inserm U1116, CHRU Nancy Brabois, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), 4 rue du Morvan, Nancy, 54500, France
Lamiral, Zohra; Université de Lorraine, Centre d'Investigation Clinique Plurithématique Inserm CIC P 1433, Inserm U1116, CHRU Nancy Brabois, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), 4 rue du Morvan, Nancy, 54500, France
Duarte, Kevin; Université de Lorraine, Centre d'Investigation Clinique Plurithématique Inserm CIC P 1433, Inserm U1116, CHRU Nancy Brabois, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), 4 rue du Morvan, Nancy, 54500, France
Merkling, Thomas; Université de Lorraine, Centre d'Investigation Clinique Plurithématique Inserm CIC P 1433, Inserm U1116, CHRU Nancy Brabois, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), 4 rue du Morvan, Nancy, 54500, France
Merckle, Ludovic; Université de Lorraine, Centre d'Investigation Clinique Plurithématique Inserm CIC P 1433, Inserm U1116, CHRU Nancy Brabois, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), 4 rue du Morvan, Nancy, 54500, France
Bozec, Erwan; Université de Lorraine, Centre d'Investigation Clinique Plurithématique Inserm CIC P 1433, Inserm U1116, CHRU Nancy Brabois, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), 4 rue du Morvan, Nancy, 54500, France
Dougkas, Anestis; INRAE, CarMeN Laboratory, INSERM, U1060, Univ Lyon, Université Claude Bernard Lyon 1, Bâtiment CENS-ELI 2D, Hopital Lyon Sud, 165 Chemin du Grand Revoyet, Pierre-Bénite, 69310, France ; Institute Lyfe Research Centre, Chateau Du Vivier, BP 25, 69131, Ecully Cedex, France
Hoge, Axelle ; Université de Liège - ULiège > Département des sciences de la santé publique
Guillaume, Michèle ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique : aspects spécifiques
Rossignol, Patrick; Université de Lorraine, Centre d'Investigation Clinique Plurithématique Inserm CIC P 1433, Inserm U1116, CHRU Nancy Brabois, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), 4 rue du Morvan, Nancy, 54500, France ; Medicine and Nephrology-Dialysis Departments, Princess Grace Hospital, and Monaco Private Hemodialysis Centre, Monaco, Monaco
Nazare, Julie-Anne; INRAE, CarMeN Laboratory, INSERM, U1060, Univ Lyon, Université Claude Bernard Lyon 1, Bâtiment CENS-ELI 2D, Hopital Lyon Sud, 165 Chemin du Grand Revoyet, Pierre-Bénite, 69310, France ; Centre de Recherche en Nutrition Humaine - Rhône-Alpes, CRNH-RA, INSERM, INRAE, Université Claude Bernard Lyon 1, Hospices Civils de Lyon, Pierre-Bénite, France
Vors, Cécile; INRAE, CarMeN Laboratory, INSERM, U1060, Univ Lyon, Université Claude Bernard Lyon 1, Bâtiment CENS-ELI 2D, Hopital Lyon Sud, 165 Chemin du Grand Revoyet, Pierre-Bénite, 69310, France ; Centre de Recherche en Nutrition Humaine - Rhône-Alpes, CRNH-RA, INSERM, INRAE, Université Claude Bernard Lyon 1, Hospices Civils de Lyon, Pierre-Bénite, France
Boivin, Jean-Marc; Université de Lorraine, Centre d'Investigation Clinique Plurithématique Inserm CIC P 1433, Inserm U1116, CHRU Nancy Brabois, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), 4 rue du Morvan, Nancy, 54500, France ; Department of General Medicine, University of Lorraine, Vandoeuvre-lès- Nancy, France
Michalski, Marie-Caroline ; INRAE, CarMeN Laboratory, INSERM, U1060, Univ Lyon, Université Claude Bernard Lyon 1, Bâtiment CENS-ELI 2D, Hopital Lyon Sud, 165 Chemin du Grand Revoyet, Pierre-Bénite, 69310, France. Marie-Caroline.Michalski@inrae.fr ; Centre de Recherche en Nutrition Humaine - Rhône-Alpes, CRNH-RA, INSERM, INRAE, Université Claude Bernard Lyon 1, Hospices Civils de Lyon, Pierre-Bénite, France. Marie-Caroline.Michalski@inrae.fr
FRM - Fondation pour la Recherche Médicale CHU Nancy - Centre Hospitalier Universitaire de Nancy FEDER - Fonds Européen de Développement Régional ANR - Agence Nationale de la Recherche EU - European Union
Funding text :
M.-C. M. received research funding from CNIEL, Sodiaal-Candia R&I, and Danone Nutricia Research, congress travel funding from CNIEL and symposium honorarium from IMGC, which are not related to the present epidemiological study. PR received grants and personal fees from Vifor Fresenius Medical Care Renal Pharma, personal fees from Idorsia, personal fees from KBP, Sanofi, NovoNordisk, personal fees from Ablative Solutions, non-financial support from G3P, personal fees from Corvidia, grants, personal fees from Relypsa, a Vifor company, and Vifor, personal fees from CardioRenal, grants and personal fees from AstraZeneca, grants and personal fees from Bayer, grants and personal fees from CVRx, personal fees from Fresenius, grants and personal fees from Novartis, personal fees from Grunenthal, personal fees from Servier, personal fees from Stealth Peptides, all outside the submitted work. NG received honoraria from AstraZeneca, Bayer, Boehringer, Echosens, Lilly, Roche diagnostics, Novartis. PR: reports consulting for Idorsia, G3P, honoraria from AstraZeneca, Bayer, Boehringer-Ingelheim, Cincor, CVRx, Fresenius, KBP biosciences, Novartis, NovoNordisk, Relypsa, Servier, and Vifor Fresenius Medical Care Renal Pharma; and travel grants from AstraZeneca, Bayer, CVRx, Novartis, and Vifor Fresenius Medical Care Renal Pharma; Cofounder: CardioRenal, all outside the submitted work. The other co-authors have no conflicts of interest to disclose related to the submitted work, and declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.This work was funded by the FRM (Fondation pour la Recherche M\u00E9dicale, DAILICATE project, Equipe FRM EQU202103012668, coordinated by M.C. Michalski). The fourth examination of the STANISLAS study was sponsored by the Centre Hospitalier R\u00E9gional Universitaire of Nancy (CHRU) and the French Ministry of Health (Programme Hospitalier de Recherche Clinique Inter-r\u00E9gional 2013), by the Contrat de Plan Etat\u2010 Lorraine and \u201CFonds Europ\u00E9en de D\u00E9veloppement R\u00E9gional\u201D (FEDER Lorraine), and by a public grant overseen by the French National Research Agency (ANR) as part of the second \u201CInvestissements d\u2019Avenir\u201D program FIGHT\u2010HF (reference: ANR\u201015\u2010RHU\u20100004) and by the French \u201CProjet investissement d\u2019avenir\u201D (PIA) project \u201CLorraine Universit\u00E9 d\u2019Excellence\u201D (reference ANR\u201015\u2010IDEX\u201004\u2010LUE). The STANISLAS study is also supported by the sixth European Union\u2014Framework Program (EU-FP) Network of Excellence Ingenious HyperCare (#LSHM-CT-2006\u2013037093), the seventh EU-FP MEDIA (Europ\u00E9en Cooperation\u2014Theme Health/FP7HEALTH-2010-single-stage #261409), HOMAGE (Heart Omics in Aging, 7th Framework Program grant #305507), FOCUS-MR (reference: ANR-15-CE14-0032-01), and FIBROTARGETS (FP7#602904) projects, and by ERA-CVD EXPERT (reference: ANR-16-ECVD-0002-02).
Guillocheau E, Milard M, Rioux V et al (2020) Nutritional significance of milk lipids: from bioactive fatty acids to supramolecular structures impacting metabolism. In: McSweeney PLH, Fox PF, O’Mahony JA (eds) Advanced dairy chemistry, volume 2: lipids. Springer, Cham, pp 307–344 https://doi.org/10.1007/978-3-030-48686-0_10
A. Eilander R.K. Harika P.L. Zock Intake and sources of dietary fatty acids in europe: are current population intakes of fats aligned with dietary recommendations? Eur J Lipid Sci Technol 117 1370 1377 10.1002/ejlt.201400513 26877707 4736684
S. Harrison S. Lemieux B. Lamarche Assessing the impact of replacing foods high in saturated fats with foods high in unsaturated fats on dietary fat intake among Canadians Am J Clin Nutr 115 877 885 10.1093/ajcn/nqab420 34958344
K.C. Maki M.R. Dicklin C.F. Kirkpatrick Saturated fats and cardiovascular health: current evidence and controversies J Clin Lipidol 15 765 772 10.1016/j.jacl.2021.09.049 34649831
The Central Committee for Medical and Community Program of the American Heart Association Dietary fat and its relation to heart attacks and strokes Rep JAMA 175 389 391
Guidelines Review Committee Nutrition and food safety (NFS) saturated fatty acid and trans-fatty acid intake for adults and children: WHO guidelines, World Health Organization
D. Mozaffarian I. Rosenberg R. Uauy History of modern nutrition science—implications for current research, dietary guidelines, and food policy BMJ 361 k2392 10.1136/bmj.k2392 29899124 5998735
Z. Harcombe US dietary guidelines: is saturated fat a nutrient of concern? Br J Sports Med 53 1393 1396 10.1136/bjsports-2018-099420 30108061
P.W. Siri-Tarino Q. Sun F.B. Hu R.M. Krauss Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease12345 Am J Clin Nutr 91 535 546 10.3945/ajcn.2009.27725 20071648 2824152
de Souza RJ, Mente A, Maroleanu A et al Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies
L. Hooper N. Martin O.F. Jimoh et al. Reduction in saturated fat intake for cardiovascular disease Cochrane Database Syst Reviews 10.1002/14651858.CD011737.pub3
A. Astrup F. Magkos D.M. Bier et al. Saturated fats and health: A reassessment and proposal for Food-Based recommendations: JACC State-of-the-Art review J Am Coll Cardiol 76 844 857 10.1016/j.jacc.2020.05.077 32562735
M.C. de Oliveira Otto D. Mozaffarian D. Kromhout et al. Dietary intake of saturated fat by food source and incident cardiovascular disease: the Multi-Ethnic study of atherosclerosis Am J Clin Nutr 96 397 404 10.3945/ajcn.112.037770 22760560 3396447
Dunne S, Gibney ER, McGillicuddy FC, Feeney EL (2024) The effects of saturated fat intake from dairy on CVD markers: the role of food matrices. Proc Nutr Soc 1–9. https://doi.org/10.1017/S0029665124000132
Feeney EL, McKinley MC (2020) Chap. 8 - The dairy food matrix: what it is and what it does. In: Givens DI (ed) Milk and dairy foods. Academic Press, pp 205–225
R.A. Goldbohm A.M.J. Chorus F. Galindo Garre et al. Dairy consumption and 10-y total and cardiovascular mortality: a prospective cohort study in the Netherlands Am J Clin Nutr 93 615 627 10.3945/ajcn.110.000430 21270377
S.S. Soedamah-Muthu E.L. Ding W.K. Al-Delaimy et al. Milk and dairy consumption and incidence of cardiovascular diseases and all-cause mortality: dose-response meta-analysis of prospective cohort studies123 Am J Clin Nutr 93 158 171 10.3945/ajcn.2010.29866 21068345
J. de Goede J.M. Geleijnse E.L. Ding S.S. Soedamah-Muthu Effect of cheese consumption on blood lipids: a systematic review and meta-analysis of randomized controlled trials Nutr Rev 73 259 275 10.1093/nutrit/nuu060 26011901
R. Pradeilles T. Norris L. Sellem O. Markey Effect of isoenergetic substitution of cheese with other dairy products on blood lipid markers in the fasted and postprandial state: an updated and extended systematic review and Meta-Analysis of randomized controlled trials in adults Adv Nutr 14 1579 1595 10.1016/j.advnut.2023.09.003 37717700 10721513
C. Vors L. Joumard-Cubizolles M. Lecomte et al. Milk Polar lipids reduce lipid cardiovascular risk factors in overweight postmenopausal women: towards a gut sphingomyelin-cholesterol interplay Gut 69 487 501 10.1136/gutjnl-2018-318155 31189655
F. Rosqvist A. Smedman H. Lindmark-Månsson et al. Potential role of milk fat globule membrane in modulating plasma lipoproteins, gene expression, and cholesterol metabolism in humans: a randomized study Am J Clin Nutr 102 20 30 10.3945/ajcn.115.107045 26016870
Michalski M-C, Rioux L-E, Turgeon SL (2020) Role of the matrix on the digestibility of dairy fat and health consequences. In: Truong T, Lopez C, Bhandari B, Prakash S (eds) Dairy fat products and functionality: fundamental science and technology. Springer, Cham, pp 153–202 https://doi.org/10.1007/978-3-030-41661-4_8
J.-P. Drouin-Chartier A.J. Tremblay J. Maltais-Giguère et al. Differential impact of the cheese matrix on the postprandial lipid response: a randomized, crossover, controlled trial† Am J Clin Nutr 106 1358 1365 10.3945/ajcn.117.165027 28978543
B. Lamarche A. Astrup R.H. Eckel et al. Regular-fat and low-fat dairy foods and cardiovascular diseases: perspectives for future dietary recommendations Am J Clin Nutr 121 956 964 10.1016/j.ajcnut.2025.03.009 40088974 12107492
S. Laurent J. Cockcroft L. Van Bortel et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications Eur Heart J 27 2588 2605 10.1093/eurheartj/ehl254 17000623
J.-C. Tardif T. Heinonen D. Orloff P. Libby Vascular biomarkers and surrogates in cardiovascular disease Circulation 113 2936 2942 10.1161/CIRCULATIONAHA.105.598987 16801474
J.P. Ferreira N. Girerd E. Bozec et al. Cohort profile: rationale and design of the fourth visit of the STANISLAS cohort: a Familial longitudinal population-based cohort from the Nancy region of France Int J Epidemiol 47 395 395j 10.1093/ije/dyx240 29220499
N. Sauvageot A. Alkerwi A. Albert M. Guillaume Use of food frequency questionnaire to assess relationships between dietary habits and cardiovascular risk factors in NESCAV study: validation with biomarkers Nutr J 12 143 10.1186/1475-2891-12-143 24195492 4176104
Agbo LD, Girerd N, Lamiral Z, et al. (2024) Dietary inflammatory potential and arterial stiffness in a French cohort: insights from the STANISLAS study. Nutr Metab Diseases C. https://doi.org/10.1016/j.numecd.2024.03.022
C.A. Monteiro G. Cannon R. Levy et al. NOVA. The star shines bright World Nutr 7 28 38
L.L.C.H. Xia N. Girerd Z. Lamiral et al. Association between ultra-processed food consumption and inflammation: insights from the STANISLAS cohort Eur J Nutr 64 94 10.1007/s00394-025-03607-y 39960649
P.L. Huang A comprehensive definition for metabolic syndrome Dis Model Mech 2 231 237 10.1242/dmm.001180 19407331 2675814
L.M. Van Bortel S. Laurent P. Boutouyrie et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity J Hypertens 30 445 448 10.1097/HJH.0b013e32834fa8b0 22278144
J.P. Ferreira N. Girerd E. Bozec et al. Intima-Media thickness is linearly and continuously associated with systolic blood pressure in a Population-Based cohort (STANISLAS cohort Study) J Am Heart Assoc 5 e003529 10.1161/JAHA.116.003529 27312804 4937282
Z. Frikha N. Girerd O. Huttin et al. Reproducibility in echocardiographic assessment of diastolic function in a population based study (The STANISLAS cohort study) PLoS ONE 10 e0122336 10.1371/journal.pone.0122336 25853818 4390157
S.F. Nagueh C.P. Appleton T.C. Gillebert et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography Eur J Echocardiogr 10 165 193 10.1093/ejechocard/jep007 19270053
C. Cuspidi V. Giudici F. Negri et al. Improving cardiovascular risk stratification in essential hypertensive patients by indexing left ventricular mass to height(2.7) J Hypertens 27 2465 2471 10.1097/HJH.0b013e32833105a6 19898252
G. de Simone R.B. Devereux S.R. Daniels et al. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk J Am Coll Cardiol 25 1056 1062 10.1016/0735-1097(94)00540-7 7897116
W.T. Friedewald R.I. Levy D.S. Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 499 502 4337382
G. Mancia R. Kreutz M. Brunström et al. 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European society of hypertension: endorsed by the international society of hypertension (ISH) and the European renal association (ERA) J Hypertens 41 1874 2071 10.1097/HJH.0000000000003480 37345492
D. Bates M. Mächler B. Bolker S. Walker Fitting linear Mixed-Effects models using lme4 J Stat Softw 67 1 48 10.18637/jss.v067.i01
M. Yuan M.R. Singer R.T. Pickering L.L. Moore Saturated fat from dairy sources is associated with lower cardiometabolic risk in the Framingham offspring study Am J Clin Nutr 116 1682 1692 10.1093/ajcn/nqac224 36307959 9761752
Z.L. Li Y.Q. Zhang Q. Zhang et al. [Association of dairy intake frequency with left ventricular hypertrophy in childhood] Zhonghua Yu Fang Yi Xue Za Zhi 54 1389 1395 10.3760/cma.j.cn112150-20200610-00853 33333656
V. Bhupathi M. Mazariegos J.B. Cruz Rodriguez A. Deoker Dairy intake and risk of cardiovascular disease Curr Cardiol Rep 22 11 10.1007/s11886-020-1263-0 31997094
M.U. Jakobsen E. Trolle M. Outzen et al. Intake of dairy products and associations with major atherosclerotic cardiovascular diseases: a systematic review and meta-analysis of cohort studies Sci Rep 11 1303 10.1038/s41598-020-79708-x 33446728 7809206
Z. Chen M. Ahmed V. Ha et al. Dairy product consumption and cardiovascular health: A systematic review and Meta-analysis of prospective cohort studies Adv Nutr 13 439 454 10.1093/advances/nmab118 34550320
J. Fontecha M.V. Calvo M. Juarez et al. Milk and dairy product consumption and cardiovascular diseases: an overview of systematic reviews and Meta-Analyses Adv Nutr 10 S164 S189 10.1093/advances/nmy099 31089735 6518146
G.B.J. Mancini B. Dahlöf J. Díez Surrogate markers for cardiovascular disease Circulation 109 IV 22 10.1161/01.CIR.0000133443.77237.2f
J. Companys A. Pedret R.M. Valls et al. Fermented dairy foods rich in probiotics and cardiometabolic risk factors: a narrative review from prospective cohort studies Crit Rev Food Sci Nutr 61 1966 1975 10.1080/10408398.2020.1768045 32436399
L. Sellem B. Srour K.G. Jackson et al. Consumption of dairy products and CVD risk: results from the French prospective cohort NutriNet-Santé Br J Nutr 127 752 762 10.1017/S0007114521001422 33910667
A.D. Sniderman G. Thanassoulis T. Glavinovic et al. Apolipoprotein B particles and cardiovascular disease: A narrative review JAMA Cardiol 4 1287 1295 10.1001/jamacardio.2019.3780 31642874 7369156
S.S. Carr A.J. Hooper D.R. Sullivan J.R. Burnett Non-HDL-cholesterol and Apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment Pathology 51 148 154 10.1016/j.pathol.2018.11.006 30595507
A.D. Sniderman ApoB vs non-HDL-C vs LDL-C as markers of cardiovascular disease Clin Chem 67 1440 1442 10.1093/clinchem/hvab140 34535997
Y.R. Ranjbar J. Nasrollahzadeh Comparison of the impact of saturated fat from full-fat yogurt or low-fat yogurt and butter on cardiometabolic factors: a randomized cross-over trial Eur J Nutr 63 1213 1224 10.1007/s00394-024-03352-8 38367032
F. Rul C. Béra-Maillet M.C. Champomier-Vergès et al. Underlying evidence for the health benefits of fermented foods in humans Food Funct 13 4804 4824 10.1039/D1FO03989J 35384948
Tamang JP, Shin D-H, Jung S-J, Chae S-W (2016) Functional properties of microorganisms in fermented foods. Front Microbiol 7. https://doi.org/10.3389/fmicb.2016.00578
A.K. Rai S. Sanjukta K. Jeyaram Production of angiotensin I converting enzyme inhibitory (ACE-I) peptides during milk fermentation and their role in reducing hypertension Crit Rev Food Sci Nutr 57 2789 2800 10.1080/10408398.2015.1068736 26463100
H. Aslam W. Marx T. Rocks et al. The effects of dairy and dairy derivatives on the gut microbiota: a systematic literature review Gut Microbes 12 1799533 10.1080/19490976.2020.1799533 32835617 7524346
D. Aune T. Norat P. Romundstad L.J. Vatten Dairy products and the risk of type 2 diabetes: a systematic review and dose-response meta-analysis of cohort studies123 Am J Clin Nutr 98 1066 1083 10.3945/ajcn.113.059030 23945722
Z. Gaeini Z. Bahadoran P. Mirmiran Saturated fatty acid intake and risk of type 2 diabetes: an updated systematic review and Dose-Response Meta-Analysis of cohort studies Adv Nutr 13 2125 2135 10.1093/advances/nmac071 36056919 9776642
US Food and Drug Administration (FDA) Response Letter to Petition for a Qualified Health Claim for Yogurt and Reduced Risk of Type 2 Diabetes Mellitus (Docket No. FDA-2019-P-1594). FDA
A. Koutsos B.A. Griffin R. Antoni et al. Variation of LDL cholesterol in response to the replacement of saturated with unsaturated fatty acids: a nonrandomized, sequential dietary intervention; the reading, imperial, surrey, saturated fat cholesterol intervention (RISSCI-1) study Am J Clin Nutr 120 854 863 10.1016/j.ajcnut.2024.07.032 39111551 11473524
Khaw K-T, Sharp SJ, Finikarides L et al (2018) Randomised trial of coconut oil, Olive oil or butter on blood lipids and other cardiovascular risk factors in healthy men and women. https://doi.org/10.1136/bmjopen-2017-020167
N.F. Galeano M. Al-Haideri F. Keyserman et al. Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity J Lipid Res 39 1263 1273 9643358
N. Bergeron S. Chiu P.T. Williams et al. Effects of red meat, white meat, and nonmeat protein sources on atherogenic lipoprotein measures in the context of low compared with high saturated fat intake: a randomized controlled trial Am J Clin Nutr 110 24 33 10.1093/ajcn/nqz035 31161217 6599736
Bernic D, Brassard D, Tessier-Grenier M et al (2017) Comparing the impact of saturated fatty acids from different dairy sources on LDL particle size phenotype. FASEB J 31. https://doi.org/10.1096/fasebj.31.1_supplement.966.5. 966.5-966.5
M. Dehghan A. Mente S. Rangarajan et al. Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study Lancet 392 2288 2297 10.1016/S0140-6736(18)31812-9 30217460
T.K. Thorning H.C. Bertram J.-P. Bonjour et al. Whole dairy matrix or single nutrients in assessment of health effects: current evidence and knowledge gaps Am J Clin Nutr 105 1033 1045 10.3945/ajcn.116.151548 28404576
M. Le Barz C. Vors E. Combe et al. Milk Polar lipids favorably alter Circulating and intestinal ceramide and sphingomyelin species in postmenopausal women JCI Insight 6 e146161 10.1172/jci.insight.146161 33857018 8262315
H. Yun L. Sun Q. Wu et al. Lipidomic signatures of dairy consumption and associated changes in blood pressure and other cardiovascular risk factors among Chinese adults Hypertension 79 1617 1628 10.1161/HYPERTENSIONAHA.122.18981 35469422
J.-P. Drouin-Chartier P. Hernández-Alonso M. Guasch-Ferré et al. Dairy consumption, plasma metabolites, and risk of type 2 diabetes Am J Clin Nutr 114 163 174 10.1093/ajcn/nqab047 33742198 8246603
J.-P. Drouin-Chartier Plasma lipidomic profiles of dairy consumption: a new window on their cardiometabolic effects Hypertension 79 1629 1632 10.1161/HYPERTENSIONAHA.122.19491 35861753
C. Vors G. Pineau L. Gabert et al. Modulating absorption and postprandial handling of dietary fatty acids by structuring fat in the meal: a randomized crossover clinical trial Am J Clin Nutr 97 23 36 10.3945/ajcn.112.043976 23235199
ANSES. Avis de l’Anses (2017) Étude individuelle nationale des consommations alimentaires 3 (INCA 3). Rapport d’expertise collective. https://www.anses.fr/sites/default/files/NUT2014SA0234Ra.pdf
